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Pharmacokinetics of ceftriaxone after a single dose of 50 or 75 mg/kg were
determined in 30 pediatric patients with bacterial meningitis. Data for doses of 50
and 75 mg/kg, respectively, were as follows (mean ± standard deviation):
maximum plasma concentrations, 230 ± 64 and 295 ± 76 ,ug/ml; elimination rate
constant, 0.14 ± 0.06 and 0.14 ± 0.04 h-1; harmonic elimination half-life, 5.8 +
2.8 and 5.4 ± 2.1 h; plasma clearance, 51 ± 24 and 55 ± 18 mI/h per kg; volume of
distribution, 382 ± 129 and 387 ± 56 ml/kg; mean concentration in cerebrospinal
fluid 1 to 6 h after infusion, 5.4 and 6.4 ,ug/ml. A dosage schedule of 50 mg/kg
every 12 h for bacterial meningitis caused by susceptible organisms is suggested
for pediatric patients over 7 days of age.
Newer 1-lactam antibiotics have been consid-
ered as an alternative to the current therapy for
bacterial meningitis. There are features unique
to these agents which make them particularly
attractive, primarily their excellent penetration
into cerebrospinal fluid (CSF), a broad spectrum
of bactericidal activity including most enteric
organisms and 3-lactamase-producing Haemo-
philus influenzae, and relatively rare toxicity.
Ceftriaxone offers additional advantages over
other 3-lactam antibiotics in its activity against
group B streptococci and relatively long half-
life.
The present study was designed to examine
ceftriaxone pharmacokinetics after a single in-
travenous dose. Safety and tolerance were also
evaluated.
MATERIAULS AND METHODS
Patients and study deign. The study population
included five full-term neonates, 8 to 21 days, and 25
infants, aged 6 weeks to 2 years, who were receiving
conventional therapy for documented bacterial menin-
gitis at Arkansas Children's Hospital, Little Rock.
Written informed consent was obtained from the par-
ents of all participants. Between days 2 and 5 of
therapy, when infection was judged to be under ade-
quate control, and without alteration of the antimicro-
bial regimen, a single dose of ceftriaxone was adminis-
tered intravenously over a 10-min period. The study
was randomized so that halfof the patients received 50
mg/kg and half received 75 mg/kg for this one infusion.
Plasma samples were obtained just before infusion and
at 15, 30, and 60 min and 2, 4, 6, and 10 h after
infusion. A lumbar puncture was performed 1 to 6 h
after drug administration, and a sample of CSF was
obtained for analysis of ceftriaxone concentration.
Susceptibility studies. Mean inhibitory concentra-
tions (MICs) of ceftriaxone for each pathogen were
determined by standard microtiter broth dilution (6).
An inoculum of 105 organisms per ml in logarithmic
growth phase was introduced into wells containing
appropriate nutrients for that organism and serial
dilutions of ceftriaxone.
Cftriaxone concentrations. Plasma and CSF con-
centrations of ceftriaxone were analyzed by high-
pressure liquid chromatographic techniques (9). To
monitor ceftriaxone levels on a daily basis for patients
receiving this investigational antibiotic, microbiologi-
cal methodology was employed; briefly, this was a
standard agar well diffusion assay in which susceptible
Escherichia coli is used after dilution of the specimen
with pooled plasma (1).
Pharmacokinetic determinations. The elimination
rate constant, 1, was determined from the regression
line of the log plasma concentrations versus time by
the NONLIN computer program (8). Serum half-life,
tV2, was calculated from the equation: t1/2 = 0.693/,B.
Successive trapezoidal approximations and extrapola-
tion were used to calculate the area under the serum
concentration-time curve from time zero to infinity.
Plasma clearance (Clp) was derived from the equation:
Clp = dose/area under the serum concentration-time
curve. The volume of distribution, Vd, was determined
from the equation: Vd = dose/(Clp x 1) (10).
Clinical and laboratory studies. Patients were care-
fully monitored for adverse reactions during infusion
by one of the investigators and followed during the
duration of hospitalization. In addition, laboratory
parameters for bone marrow, renal, or hepatic toxicity
were obtained preinfusion and at 2 and 4 days. These
included CBC, blood urea nitrogen, creatinine, urinal-
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TABLE 1. Organisms recovered from 30 patients
with bacterial meningitis
No. of Susceptibility to
Organism patients cdftriaxone (pg/ml)
Haemophilus
f-Lactamase (-) 10 50.06
f-Lactamase (+) 3 sO.06-0.125
Streptococcus 3 50.06-0.25
pneumoniae
Neisseria meningitidis 4 50.03
Escherichia coli 3 50.03-0.25
Group B streptoccoci 2 50.06
Staphylococcus 2 2.0-4.0
aureus
Listeria 2 64
monocytogenes
Bacillus sp. 1 8
ysis, serum glutamic oxalacetic transaminase, and
serum glutamic pyruvic transaminase.
RESULTS
Pathogens recovered from these 30 cases,
along with their susceptibilities to ceftriaxone,
as determined by MICs, are included in Table 1.
Predictably, the organisms most frequently iso-
lated from infants were H. influenzae. All recov-
ered organisms except two isolates of Listeria
monocytogenes and one Bacillus sp. were sus-
ceptible to ceftriaxone at concentrations well
below the range of those achieveable in CSF;
these three resistant organisms were recovered
from neonates. Two CSF isolates of Staphylo-
coccus aureus from infants with ventriculoperi-
toneal shunts, previously placed for hydroceph-
alus, were susceptible at 2 and 4 ,ug/ml.
Results for the five neonates, all over 7 days
of age, were not different from those for infants
in the present study, so determinations were
combined for analysis. Pharmacokinetic data are
summarized in Table 2 and Fig. 1.
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Most importantly, concentrations in CSF
were usually 10 to 100 times greater than the
MIC for recovered bacteria. The measured lev-
els of ceftriaxone in the two infants with S.
aureus were two- to threefold higher than the
MIC for those organisms. Other exceptions in-
cluded three resistant organisms already de-
scribed.
Ceftriaxone administered intravenously over
a 10-min period was well tolerated by infants and
neonates, with no local or systemic reactions
observed. There were no changes in laboratory
parameters used to assess bone marrow, renal,
or hepatic toxicity.
CSF drug concentrations are presented in
Table 2 simply as the mean for all samples
obtained; the wide variation in the time that CSF
was obtained (1 to 6 h) prevents a full statistical
analysis of penetration into CSF for these study
subjects. The CSF-to-plasma concentration ra-
tio ranged from 1.8 to 24.6% after a single dose.
Results for individual patients are presented in
Fig. 2. Mean values expressed as a percentage of
plasma levels were as follows for the 50-mg/kg
dose: 4.8% at 2 h, 11.8% at 3 h, 3.5% at 4 h,
14.6% at 5 h, and 10.0%o at 6 h. For the 75-mg/kg
dose, the percent penetration was 6.2% at 2 h,
7.7% at 3 h, 4.8% at 4 h, 3.5% at 5 h, and 12.9%
at 6 h.
DISCUSSION
Previously published studies have demon-
strated the in vitro activity of ceftriaxone against
a wide variety of gram-positive and gram-nega-
tive bacteria (5, 7, 14). Pertinent to consider-
ations of meningitis therapy are susceptibilities
of the three major etiological agents causing
disease in infants and those two most commonly
associated with infection in neonates. The con-
centration (in micrograms per milliliter) of cef-
triaxone inhibiting 90%o of clinical isolates in
vitro were as follows: H. influenzae, <0.004;
Neisseria meningitidis, 0.004; Streptococcus
pneumoniae, 0.03; E. coli, 0.12; and group B
streptococci, 0.10.
Subsequent studies in a rabbit meningitis
model (11) demonstrated penetration into the
CSF at a concentration that was >7% of the
TABLE 2. Ceftriaxone pharmacokinetics for infants and children
Pharmacokinetic data
Dose (mg/lcg) C Maximum CSF
)t(h-) (ml/hperkCg Vd (m/kg) plasma concn concnDose(mg/kg)~ h-1) t½pQE) per kg) (g4/ml) (Pg/mi)
50 0.14 ± 0.06 5.8 ± 2.8 51 + 24 382 ± 129 230 ± 64 5.4
75 0.14 ± 0.04 5.4 + 2.1 55± 18 387± 56 295 ± 76 6.4
a Elimition rate constant; t7p, elimination half-life, Clp, plasma clearance; Vd, volume of distribution.
Values are expressed as means + standard deviation.
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FIG. 1. Dose and mean plasma concentration-time
curves + standard deviation after a single intravenous
infusion of ceftriaxone.
concomitant serum levels. Compared with other
P-lactam antibiotics, ceftriaxone exhibited the
longest half-life and duration of bactericidal ac-
tivity and was the most effective in reducing
bacterial counts of E. coli and group B strepto-
coccus type III test strains in CSF.
Initial pharmacokinetic data in normal adult
volunteers indicated an elimination half-life of
approximately 8 h (2, 13). Similar studies in five
infants and five young children demonstrated a
slightly lower half-life at 6.5 h (12).
Preliminary studies for the treatment of bacte-
rial meningitis in neonates, infants, and children
have been published (4). Clinical efficacy and
tolerance studies in adults with serious bacterial
infections have recently been published and
have established ceftriaxone as an agent with a
high degree of efficacy and a low incidence of
toxicity (3, 7). These reports support its selec-
tion as single drug therapy for a variety of
clinical presentations.
The present studies have focused on aspects
of meningitis therapy in children primarily to
establish dosage recommendations for future
treatment protocols and to examine CSF drug
levels relative to susceptibility of invading
pathogens. A tentative dosage schedule of 100
mg/kg given in two intravenous infusions every
24 h is suggested. Preliminary results in a recent-
ly completed comparative clinical trial of cef-
triaxone versus standard therapy for bacterial
meningitis have confirmed these recommenda-
tions (R. W. Steele and R. W. Bradsher, Pro-
gram Abstr. Intersci. Conf. Antimicrob. Agents
Chemother. 22nd, Atlantic City, N.J., abstr. no.
317, 1982).
Most important for the treatment of meningitis
are data concerning penetration of antibiotics
into CSF. CSF levels 5 to 10% of concomitant
plasma concentrations are comparable to those
previously reported in animal models (11) and
human studies (4). These CSF levels exceeded
the MIC for common pathogens by at least 10-
fold; this appears to be the most critical deter-
mining factor for success of therapy.
These and other studies indicate that ceftriax-
one would not be effective for meningitis caused
by L. monocytogenes or enterococci and must
be considered of questionable value for the
treatment of Pseudomonas aeruginosa and S.
aureus meningitis. When any of these pathogens
are initially suspected, ceftriaxone should be
used in combination with other agents pending
results of cultures and susceptibility tests.
Repeated measurement of antibiotic levels is
important in monitoring the adequacy of antimi-
crobial therapy. In the present studies, a simple
microbiological assay was comparable to high-
pressure liquid chromatographic methodology
for assaying serum and CSF concentrations of
drug. Thus, more ready application in the usual
clinical setting of a medical center is ensured.
In summary, we found that ceftriaxone pene-
trated into the CSF of infants and neonates to a
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FIG. 2. CSF concentrations of ceftriaxone at vari-
ous times after a single intravenous dose of 50 mg/kg(0) or 75 mg/kg (0) in 30 pediatric patients with
bacterial meningitis.
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degree that should provide adequate levels to
treat the usual bacterial causes of meningitis.
The measured plasma half-life was longer than
those of other cephalosporins and investigation-
al P-lactam antibiotics, ensuring a greater dura-
tion of bactericidal activity for individual doses.
These initial pharmacokinetic data establish a
tentative dosage schedule of 50 mg/kg every 12 h
for the treatment of meningitis in pediatric pa-
tients over 7 days of age.
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